Pemafibrate: First Global Approval. (Q50001874)

23 February 2018

title

Pemafibrate: First Global Approval. (English)

1 reference

23 February 2018

author name string

Hannah A Blair

series ordinal

1

1 reference

23 February 2018

publication date

19 September 2017

1 reference

23 February 2018

published in

Drugs

1 reference

23 February 2018

volume

77

1 reference

23 February 2018

page(s)

1805-1810

1 reference

23 February 2018

issue

16

1 reference

23 February 2018

https://scigraph.springernature.com/pub.10.1007/s40265-017-0818-x

exact match

0 references

cites work

Selective peroxisome proliferator-activated receptor-α modulator K-877 efficiently activates the peroxisome proliferator-activated receptor-α pathway and improves lipid metabolism in mice.

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0818-X

Transcriptome Analysis of K-877 (a Novel Selective PPARα Modulator (SPPARMα))-Regulated Genes in Primary Human Hepatocytes and the Mouse Liver.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0818-X

Effects of K-877, a novel selective PPARα modulator, on small intestine contribute to the amelioration of hyperlipidemia in low-density lipoprotein receptor knockout mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0818-X

A Novel Selective PPARα Modulator (SPPARMα), K-877 (Pemafibrate), Attenuates Postprandial Hypertriglyceridemia in Mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0818-X

Efficacy and safety of K-877, a novel selective peroxisome proliferator-activated receptor α modulator (SPPARMα), in combination with statin treatment: Two randomised, double-blind, placebo-controlled clinical trials in patients with dyslipidaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0818-X

Effects of K-877, a novel selective PPARα modulator (SPPARMα), in dyslipidaemic patients: A randomized, double blind, active- and placebo-controlled, phase 2 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0818-X

The novel selective PPARα modulator (SPPARMα) pemafibrate improves dyslipidemia, enhances reverse cholesterol transport and decreases inflammation and atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0818-X

10.1007/S40265-017-0818-X

21 January 2018

Identifiers

DOI

1 reference

23 February 2018

PubMed ID

28929345

1 reference

23 February 2018